Abstract
Severe asthma is a high-cost chronic disease with different inflammatory phenotypes, the eosinophilic phenotype being the most common. Benralizumab is a monoclonal antibody that targets this phenotype. This study evaluated the cost-utility ratio of Benralizumab in patients with severe eosinophilic asthma in Panama.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
